日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data

利用真实世界数据和NATALEE数据,基于机器学习预测HR+/HER2-早期乳腺癌远处复发风险和瑞博西尼治疗效果

Howard, Frederick M; Fasching, Peter A; Santa-Maria, Cesar A; Lim, Elgene; Sparano, Joseph A; Lustberg, Maryam B; Bachelot, Thomas; Blyuss, Oleg; Brezden-Masley, Christine; Park, Yeon Hee; Akdere, Murat; Ye, Fen; Pantoja, Kristyn; Kurz, Christoph; Dominguez Castro, Patricia; Razavi, Pedram

Standardized patient coaching improves therapy persistence in patients with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer treated with abemaciclib

标准化患者指导可提高接受阿贝西利治疗的激素受体阳性、HER2阴性晚期/转移性乳腺癌患者的治疗依从性。

Welslau, Manfred; Fasching, Peter A; Semmler-Lins, Nicole; Mueller, Lothar; Belleville, Erik; Rieger, Lorenz; Uhrig, Sabrina; Zahn, Mark-Oliver; Lex, Benno; Uleer, Christoph; Deuerling, Natalija; Hesse, Tobias; Langanke, Dagmar; Häberle, Lothar; Tesch, Hans

Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer

大规模荟萃分析和精准功能分析确定了FANCM区域中PTV赋予ER阴性和三阴性乳腺癌不同风险的基因表达谱。

Billaud, Amandine; Figlioli, Gisella; Mooser, Clémence; Casamassima, Irene; Azzoni, Violette; Srivatsa, Jahnavi; Colombo, Mara; Caleca, Laura; Ahearn, Thomas U; Andrulis, Irene L; Antoniou, Antonis C; Beckmann, Matthias W; Behrens, Sabine; Bermisheva, Marina; Bogdanova, Natalia V; Bolla, Manjeet K; Bonanni, Bernardo; Brüning, Thomas; Camp, Nicola J; Campbell, Archie; Castelao, Jose E; Cessna, Melissa H; Chang-Claude, Jenny; Czene, Kamila; Dennis, Joe; Devilee, Peter; Dörk, Thilo; Dunning, Alison M; Eriksson, Mikael; Evans, D Gareth; Fasching, Peter A; Figueroa, Jonine D; Gabrielson, Marike; Gago-Dominguez, Manuela; González-Neira, Anna; Guénel, Pascal; Hadjisavvas, Andreas; Hahnen, Eric; Hamann, Ute; Hillemanns, Peter; Hollestelle, Antoinette; Hooning, Maartje J; Hoppe, Reiner; Howell, Anthony; Jakubowska, Anna; Kristensen, Vessela N; Lubiński, Jan; Lush, Michael; Manoukian, Siranoush; Mavroudis, Dimitrios; Milne, Roger L; Mulligan, Anna Marie; Newman, William G; Obi, Nadia; Panayiotidis, Mihalis I; Pita, Guillermo; Rashid, Muhammad U; Rhenius, Valerie; Saloustros, Emmanouil; Sawyer, Elinor J; Schmutzler, Rita K; Shah, Mitul; Southey, Melissa C; Spurdle, Amanda B; Tomlinson, Ian; Truong, Thérèse; Wang, Qin; Wendt, Camilla; Auer, Paul L; Boddicker, Nicholas J; Bodelon, Clara; Burnside, Elizabeth S; Chen, Fei; Couch, Fergus J; Domchek, Susan M; Eliassen, Heather A; Haiman, Christopher; Hodge, James M; Hu, Chunling; Huang, Hongyan; Lindstrom, Sara; Martinez, Maria Elena; Nathanson, Katherine L; Neuhausen, Susan L; O'Brien, Katie M; Olson, Janet E; Palmer, Julie R; Patel, Alpa V; Ruddy, Kathryn J; Sandler, Dale P; Teras, Lauren R; Weinberg, Clarice R; Weitzel, Jeffrey N; Winham, Stacey J; Yadav, Siddhartha; Yao, Song; Zirpoli, Gary; Janatova, Marketa; Kleibl, Zdenek; Kleiblova, Petra; Soukupova, Jana; Zhao, Qihong; Devereux, Lisa; James, Paul A; Campbell, Ian G; Nguyen-Dumont, Tu; Dowty, James G; Andrieu, Nadine; Lesueur, Fabienne; Stoppa-Lyonnet, Dominique; Hoya, Miguel de la; Radice, Paolo; Sørensen, Claus Storgaard; Peterlongo, Paolo

Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer

肿瘤突变可预测原发性HER2阳性乳腺癌对HER2靶向治疗的耐药性

Van Mackelenbergh, Marion T; Pfarr, Nicole; Weber, Karsten; Untch, Michael; Solbach, Christine; Schneeweiss, Andreas; Jank, Paul; Blohmer, Jens; Treue, Denise; Schmatloch, Sabine; Lehmann, Annika; Hanusch, Claus; Link, Theresa; Sers, Christine; Bjelic-Radisic, Vesna; Hummel, Michael; Huober, Jens; Schmitt, Wolfgang D; Fasching, Peter A; Aktas, Bahriye; Rhiem, Kerstin; Reinisch, Mattea; Nekljudova, Valentina; Denkert, Carsten; Loibl, Sibylle

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry

使用奥拉帕尼和他拉唑帕尼抑制PARP活性治疗HER2阴性晚期乳腺癌——来自前瞻性PRAEGNANT注册研究的结果

Hörner, Manuel; Hartkopf, Andreas; John, Nelson; Ziegler, Philipp; Häberle, Lothar; Uhrig, Sabrina; Goossens, Chloë; Amann, Niklas; Cieslik, Jan-Philipp; Tretschock, Lara M; Dannehl, Dominik; Deutsch, Thomas M; Dimpfl, Moritz; Ehlert, Max; Eichstädt, Kathleen; Englisch, Alexander; Köpke, Melitta B; Krückel, Annika; Link, Theresa; Müller, Annika; Reinhardt, Kristin; Roth, Jonas; Schäffler, Henning; Sych, Lea; Tauber, Nikolas; Tegeler, Christian M; Wichmann, Catharina; Banys-Paluchowski, Maggie; Princk, Henriette; Rody, Achim; Brucker, Sara Y; Ditsch, Nina; Ettl, Johannes; Fehm, Tanja; Hack, Carolin C; Hadji, Peyman; Hein, Alexander; Janni, Wolfgang W; Kolberg, Hans-Christian; Lüftner, Diana; Lux, Michael P; Müller, Volkmar; Taran, Florin-Andrei; Tesch, Hans; Wallwiener, Diethelm; Marmé, Frederik; Seitz, Stephan; Belleville, Erik; Michel, Laura L; Wallwiener, Markus; Fasching, Peter A; Schneeweiss, Andreas; Maurer, Christian

Physiologically-Based Pharmacokinetics of Ribociclib Drug-Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast Cancer

基于生理的瑞博西尼药代动力学:药物相互作用及早期乳腺癌器官损害药代动力学

Ji, Yan; Huth, Felix; Wang, Craig; Schiller, Hilmar; Combes, Francois Pierre; Crown, John; Fasching, Peter A; Zarate, Juan Pablo; Untch, Michael

Using smart devices for prenatal care: Assessing the willingness among women with pregnancy-related anxiety

利用智能设备进行产前护理:评估有妊娠相关焦虑的女性的意愿

Altmannshofer, Stefanie; Weidenthaler, Filip; Titzmann, Adriana; Pontones, Constanza A; Danzberger, Nina; Jaeger, Katharina M; Nissen, Michael; Leutheuser, Heike; Eskofier, Bjoern M; Fasching, Peter A; Beckmann, Matthias W; Huebner, Hanna

Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer

调查 CDK4/6 抑制剂在 HR+/HER2- 晚期乳腺癌中的真实世界证据和已报道的生存结果

Sammons, Sarah; Yardley, Denise A; Sharma, Priyanka; Gadi, Vijayakrishna K; Pegram, Mark; Pathak, Purnima; Hu, Huilin; Sopher, Gary; Fasching, Peter A

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial

在德国PRAEGNANT试验中,Alpelisib和Fulvestrant被用于治疗PIK3CA突变、激素受体阳性、HER2阴性的晚期乳腺癌。

Hörner, Manuel; Tretschock, Lara M; John, Nelson; Ziegler, Philipp; Häberle, Lothar; Uhrig, Sabrina; Goossens, Chloë; Amann, Niklas; Cieslik, Jan-Philipp; Dannehl, Dominik; Deutsch, Thomas M; Dimpfl, Moritz; Ehlert, Max; Eichstädt, Kathleen; Englisch, Alexander; Köpke, Melitta B; Krückel, Annika; Link, Theresa; Müller, Annika; Reinhardt, Kristin; Roth, Jonas; Schäffler, Henning; Sych, Lea; Tegeler, Christian M; Wichmann, Catharina; Banys-Paluchowski, Maggie; Princk, Henriette; Rody, Achim; Brucker, Sara Y; Ditsch, Nina; Ettl, Johannes; Fehm, Tanja; Hack, Carolin C; Hadji, Peyman; Hein, Alexander; Janni, Wolfgang W; Kolberg, Hans-Christian; Lüftner, Diana; Lux, Michael P; Müller, Volkmar; Schneeweiss, Andreas; Taran, Florin-Andrei; Tesch, Hans; Wallwiener, Diethelm; Marmé, Frederik; Seitz, Stephan; Belleville, Erik; Hartkopf, Andreas; Michel, Laura L; Wallwiener, Markus; Fasching, Peter A; Tauber, Nikolas

Acceptance, Perceived Usefulness, and Data Sharing in Mobile Health Apps Among Patients With Breast Cancer: Cross-Sectional Survey Study

乳腺癌患者对移动健康应用程序的接受度、感知有用性和数据共享:横断面调查研究

Flaucher, Madeleine; Ott, Tabea; Nissen, Michael; Dabrock, Peter; Huebner, Hanna; Beckmann, Matthias W; Fasching, Peter A; Leutheuser, Heike; Eskofier, Bjoern M; Mocker, Alexander